Guselkumab

CHARLOTTE, N.C. — In a Healio video exclusive, David T. Rubin, MD, FACG, reported guselkumab induced greater improvement across key outcomes compared with placebo among patients with moderate to severe ulcerative colitis.

Guselkumab performed comparably in a real-world study of patients with moderate to severe plaque psoriasis as it had in previous clinical trials, according to study findings.

MILAN — Individuals with psoriasis who responded well to guselkumab maintained disease control with every 16-week dosing, possibly lengthening the dosing interval for some patients.

Guselkumab demonstrates sustained benefits for multiple, diverse manifestations of psoriatic arthritis through 1 year, according to data published in Rheumatology.

Compared with a number of other biologics used to treat psoriasis, guselkumab was associated with strong long-term drug survival as a function of both effectiveness and safety, according to study findings.

SAN DIEGO — In this video exclusive, Remo Panaccione, MD, of the University of Calgary, discussed a study assessing the safety and efficacy of Tremfya in patients with moderately to severely active Crohn’s disease.

Healio rounded up psoriasis coverage and expert analysis presented and discussed at Maui Derm for Dermatologists in Wailea, Hawaii.

BOSTON — In this video, Lloyd S. Miller, MD, PhD, of Janssen Research & Development, summarizes Tremfya (guselkumab) data in psoriasis and psoriatic arthritis treatment presented at the American Academy of Dermatology Annual Meeting.

In this exclusive video, Bruce Sands, MD, MS, discusses Tremfya and Simponi yields higher rates of clinical response, remission and endoscopic improvements in moderate-to-severe ulcerative colitis.

A greater proportion of patients treated with Tremfya for moderate to severe ulcerative colitis achieved clinical remission at 12 weeks compared with placebo, according to Axel Dignass, MD, PhD, presenting author of a clinical study.